English
|
中文
HOME
NEWS
EVENTS
Conference
Exhibition
Laws & Regulations
About Us
CAIVD & CPCEM
CAIVD
CPCEM
VIEW
About VIEW
Editorial Board
Contact
Search
News
Home
>
News
In Vitro Diagnostic Industry in China - POCT III
2025-06-10
2. Dry Chemical Technology The biggest difference between “dry chemistry” and traditional “wet chemistry” (i.e., solution chemistry) is the media involved in the chemical reactions. In this method, the liqui..
IVD China last week: Thermo Fisher and Biomobio, Wondfo, Randox and Realbio, BD Medical
2025-06-09
Thermo Fisher and Biomobio Sign Strategic Agreement in Spatial Imaging Thermo Fisher Scientific and Biomobio have successfully concluded a strategic cooperation agreement for the EVOS S1000..
IVD China last week: Fapon and KIVDA, Agilent and MEGAROBO, WeGoBP
2025-05-27
Fapon and KIVDA Sign Strategic Agreement to Deepen China-Korea IVD Collaboration On 23 May, Fapon Biotech signed a strategic cooperation agreement with the Korea In Vitro Diagnostics Associ..
Xi arrives in Hanoi for state visit to Vietnam
2025-04-15
Chinese President Xi Jinping arrived in Hanoi on Monday to pay a state visit to Vietnam.
AdvaMed continues pressure on White House to exempt devices from tariffs
2025-04-09
AdvaMed and nine other healthcare organizations have continued to pressure the White House to exempt medical devices and critical supplies from the Trump administration’s ongoing tariff saga.
Switzerland Global Enterprise Visits CAIVD during CIIE to Foster Sino-Swiss Collaboration in In Vitro Diagnostics
2024-11-15
At the 7th China International Import Expo (CIIE), themed "New Era, Shared Future", representatives from 152 countries, regions, and organizations gathered for national and corporate exhibitions. On 8 November, Switze..
FDA Approvals in In Vitro Toxicology Testing Services: The Rise of Chinese Players
2025-08-21
From January 2024 and June 2025, the U.S. Food and Drug Administration (FDA) approved 39 in-vitro toxicology testing products through the 510(k). This period marked a significant reshaping of the global market: Chines..
Cepheid Receives Health Canada Licence for Xpert® HCV VL Fingerstick
2025-08-21
Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert® HCV VL Fingerstick, an HCV RNA test that detects and quantifies HCV directly from a drop of blood, simplifying the diagnostic pathways to speed up linkage to care and monitoring sustained virological response. Xpert HCV VL Fingerstick test is performed on the GeneXpert® system.
Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer
2025-08-21
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo® (nivolumab) alone or Opdivo (nivolumab) in combination with Yervoy® (ipilimumab). The MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
2025-08-20
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2025 and updated its financial guidance on business performance for the full-year 2025.
Medtronic reports first quarter fiscal 2026 financial results
2025-08-20
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025.
Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease
2025-08-19
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients. Developed by Fujirebio Diagnostics, Inc., the test is now available nationwide through Labcorp.
bioMérieux receives U.S. FDA 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® R/ST Panel Mini
2025-08-19
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the addition of Anterior Nasal Swab (ANS) as a validated specimen type for this panel, specifically for use with the respiratory test menu. By swabbing only the anterior part of the nasal cavity, ANS provides significantly more comfort for the patient.
In Vitro Diagnostic Industry in China - Diagnosis of Blood and Body Fluids I
2025-08-19
Blood Coagulation Analyzer and Reagents 1. Overview of Domestic Blood Coagulation Market Conventional thrombosis and hemostasis diagnostic applications are mainly concentrated on screening for blee..
IVD China last week: Danaher, Roche, YHLO, Novogene
2025-08-18
Danaher Collaborates with Shanghai National Engineering Research Center for Biochip to Jointly Launch Asia's First Intelligent In Vitro Model System On August 8, the inaugural "AI-Empowere..
Total:
3399
Pages:
227
First
Prev
1
2
3
4
..
227
Next
End